Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANIN: Nilotinib vs Dasatinib in CML-CP
NCT03079505Phase 3Terminated
- Sponsor
- Hamad Medical Corporation
- Start
- Aug 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Hamad Medical Corporation. Started Aug 2017; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03079505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079505.